AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited treatment ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...

"To the best of AstraZeneca's knowledge, the importation taxes referred to in the Appraisal Opinion relate to [cancer medications] Imfinzi and Imjudo," the company said at the time. "A fine of ...

AZN to Acquire EsoBiotec; EU Nod for Imfinzi Expanded Use AstraZeneca announced a definitive agreement to acquire Belgium-based, EsoBiotec, a leading vivo cell therapy company for a total ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the ...